Home > Insider Trading > Filing (0001567619-18-007640)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1636282	Aeglea Biotherapeutics Inc.	AGLE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532219	G. Anthony Quinn	C/O Aeglea Biotherapeutics, Inc. 901 S. Mopac Expressway, Suite 250 Austin TX 78746	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-02-15	2,000	$6.02	94,793	No	5	P	Direct
Common Stock	Acquisiton	2018-08-15	994	$9.13	95,787	No	5	P	Direct
Common Stock	Acquisiton	2018-12-07	150,000	$4.11	245,787	No	4	M	Direct
Common Stock	Acquisiton	2018-12-07	3,306	$5.46	249,093	No	4	M	Direct
Common Stock	Acquisiton	2018-12-07	18,584	$6.31	267,677	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	5	P	Direct
No	5	P	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Director Stock Option (right to buy)	Disposition	2018-12-07	150,000	$0.00	150,000	$4.11
Common Stock	Director Stock Option (right to buy)	Disposition	2018-12-07	3,306	$0.00	3,306	$5.46
Common Stock	Director Stock Option (right to buy)	Disposition	2018-12-07	18,584	$0.00	18,584	$6.31

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2027-08-30	No	4	M	Direct
1,985	2026-03-17	No	4	M	Direct
144,950	2028-02-19	No	4	M	Direct

Footnotes

These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The stock option vested and became exercisable as to 100% of the shares subject to the option on July 18, 2018, subject to the continuing service of the Reporting Person on the vesting date.
The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.